| Filed On | Filing |
|---|---|
| 27 Oct 2026 | SCHEDULE 13G/A |
| 14 Oct 2026 |
8-K: Unregistered Sales of Equity Securities; Other Events
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors |
| 08 Oct 2026 |
8-K: Other Events
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer |
| 06 Oct 2026 |
Form 3: Sawaf Aziz, EVP, Chief Financial Officer
Holds 0 shares of Common Stock |
| 01 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure
SAN FRANCISCO, Calif. October 1, 2026 – Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Aziz Sawaf, MBEE, MBA, CFA, as Executive Vice President and Chief Financial Officer (CFO), effective October 5, 2026. Mr. Sa... |
| 17 Sep 2026 | 144 |
| 09 Sep 2026 | 144 |
| 25 Aug 2026 | 144 |
| 24 Aug 2026 | 144 |
| 21 Aug 2026 | 144 |
| 12 Aug 2026 |
Form 4: More Robert J, Director
Disposed of 8,000 shares (Other Transaction) · Acquired 8,000 shares (Other Transaction) |
| 07 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 24 Jul 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 29 Jun 2026 | 144 |
| 10 Jun 2026 |
Form 4: Coughlin Timothy, Director
Received 16,000 shares as a grant or award · Granted 32,000 Stock Option (Right to Buy) |
| 10 Jun 2026 |
Form 3: Coughlin Timothy, Director
Holds 0 shares of Common Stock |
| 10 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
Loading...
